Skip to main content
SpringerLink
Log in

National Trends in Management of Pathologic Stage III Melanoma

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67. https://doi.org/10.1016/S1470-2045(16)00141-8.

    Article  PubMed  Google Scholar 

  2. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in Melanoma. N Engl J Med. 2017;376(23):2211–22. https://doi.org/10.1056/NEJMoa1613210.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30. https://doi.org/10.1016/S1470-2045(15)70122-1.

    Article  CAS  PubMed  Google Scholar 

  4. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.

    Article  CAS  PubMed  Google Scholar 

  5. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90. https://doi.org/10.1245/s10434-007-9747-3.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, et al. International center-level variation in utilization of completion lymph node dissection and adjuvant systemic therapy for sentinel lymph node positive melanoma at major referral centers. Ann Surg. 2022. https://doi.org/10.1097/SLA.0000000000005370.

    Article  PubMed  Google Scholar 

  7. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104(12):510–20. https://doi.org/10.1258/jrsm.2011.110180.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Patel S. LBA6 - Neoadjuvant versus adjuvant pembrolizumab for resected stage III–IV melanoma (SWOG S1801). Presented at the ESMO Congress, 11 Sep 2022: Paris.

Download references

Acknowledgement

The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. The CoC’s NCDB and the hospitals participating in the NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Author information

Authors and Affiliations

  1. Department of Surgery, Duke University Medical Center, Durham, NC, USA

    Kristen E. Rhodin MD, Norma E. Farrow MD, MHS, Maria Xu MD, PhD, Jay Lee MD & Georgia M. Beasley MD, MHS

  2. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA

    Douglas S. Tyler MD

Authors
  1. Kristen E. Rhodin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norma E. Farrow MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Xu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jay Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douglas S. Tyler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georgia M. Beasley MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristen E. Rhodin MD.

Ethics declarations

Disclosures

Georgia Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate, and has served on a one-time advisory board for Cardinal Health and Regeneron. She is also supported by NIH K08 CA237726-01A1. Kristen E. Rhodin is supported by NIH 1R38AI140297. Norma E. Farrow, Maria Xu, Jay Lee, and Douglas S. Tyler have no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Institutional Review Board Pro00111050 was deemed exempt by the Duke University Health System Institutional Review Board.

Conference Presentation This work was presented as an oral presentation and was runner-up in the Starr Research Forum at the Association of Women Surgeons Annual Conference, October 2022, San Diego, CA, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rhodin, K.E., Farrow, N.E., Xu, M. et al. National Trends in Management of Pathologic Stage III Melanoma. Ann Surg Oncol 30, 2586–2589 (2023). https://doi.org/10.1245/s10434-023-13101-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13101-6

Search

Navigation